Novo Nordisk Is Seeing Slowing Demand for GLP-1s Wegovy and Ozempic
Key Takeaways Novo Nordisk cut its outlook as it sees slowing demand for its GLP-1 weight loss and diabetes treatments. Third-quarter profit and revenue was short of analysts’ estimates. U.S.-listed shares of Novo Nordisk (NVO) fell after the drugmaker scaled back its outlook, citing disappointing demand for its GLP-1 weight loss and diabetes drugs as […]
Novo Nordisk Is Seeing Slowing Demand for GLP-1s Wegovy and Ozempic Read More »